NCT05431634View on ClinicalTrials.gov

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

December 1, 2022

Study Completion Date

December 31, 2022

Conditions

Safety and Tolerability

Interventions

DRUG

Experimental drug: ESK-001

Multiple doses of ESK-001

OTHER

Placebo

Placebo

Trial Locations (1)

91206

Alumis Central site, Glendale

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Alumis Inc

INDUSTRY